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Abstract
Inactivation of the RB protein is one of the most fundamental events in cancer. Coming to a
molecular understanding of its function in normal cells and how it impedes cancer development
has been challenging. Historically, the ability of RB to regulate the cell cycle placed it in a central
role in proliferative control, and research focused on RB regulation of the E2F family of
transcription factors. Remarkably, several recent studies have found additional tumour-suppressor
functions of RB, including alternative roles in the cell cycle, maintenance of genome stability and
apoptosis. These advances and new structural studies are combining to define the
multifunctionality of RB.
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The RB gene was cloned more than 25 years ago1. Since that time, its encoded protein has
been identified as a universal cell cycle regulator with a central role in controlling the
commitment of a cell to initiate DNA replication and divide2. Eliminating RB function
allows unregulated cell cycle progression and promotes tumour growth. The prominent role
that RB has in blocking proliferation has created confusion in understanding its biochemical
function. Because of this key function, most upstream events that influence cell proliferation
ultimately also affect RB function. However, it is often difficult to distinguish signalling
mechanisms that directly impinge on events in the G1 phase of the cell cycle to arrest
proliferation from those that act during other cell cycle phases and indirectly cause a G1
arrest. In the context of physiological events that have input into the cell cycle, such as
cellular differentiation, cell senescence and the response to DNA damage, it can be unclear
how directly signalling pathways actually regulate RB. For these reasons, the ongoing
debate on RB function ranges between two extreme views. One view is that RB is a
multifunctional protein acting in response to numerous stimuli to create at least as many
potential outcomes. The alternative viewpoint is that signals from many different stimuli are
ultimately channelled through cyclin-dependent kinase (CDK) regulation of RB
phosphorylation, which in turn controls the activity of E2F transcription factors, a family of
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A recent paper also describes a phosphorylation‐dependent change in RB conformation that is relevant for understanding how RB
interactions with other proteins are regulated92.
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transcriptional regulators that stimulate proliferation. Both views have merit, and ultimately
most models of RB function fall somewhere in-between, as researchers work to pinpoint its
precise function.

Author Manuscript

Most cancers find a way to impair RB function, either through direct mutation of the RB
gene or, more commonly, through the altered expression of RB regulators, which include
cyclin D, CDK4 and CDK6, and their principal inhibitor, p16 (REF. 3). Given that loss of
RB function is frequent in cancer, understanding its mechanism of action is expected to offer
crucial insight into the most fundamental properties of cancer cells. Furthermore, loss of RB
function in insects and mammals alike leads to overproliferation of cells and defects in
numerous stages of organism development. From this perspective, knowledge of RB
function promises important advances in our understanding of cancer, as well as of how
proliferative control is coordinated in development. These promises can only be realized
through a mechanistic understanding of the intricacies of RB function itself.

Author Manuscript

Much of our molecular knowledge of RB was established using cancer cell lines with
aberrant RB pathway function, or was developed before the advent of RNA interference
technologies that allow for loss‐of‐function analyses. The tools to address outstanding
questions about RB structure and function in normal cells have only recently emerged. Our
goal in this Review is to highlight these exciting recent advances in the biochemical
understanding of RB. We describe the structure of RB and how its function is regulated. In
particular, we discuss the role of key interacting protein partners that can be placed in the
context of a few regulatory pathways for which detailed biochemical information is
available. Readers who are interested in how these mechanisms are connected to broader
questions of development and homeostasis2,4, as well as cancer initiation, progression5,6 and
therapy7,8, are directed to other recent reviews specializing in these topics.

RB is a platform for multiple protein contacts
Although recent research has revealed that RB functions in diverse cellular pathways, such
as apoptosis and the cell cycle, it has also become clear that RB regulates these pathways
through the stimulation or inhibition of the activity of interacting proteins. Therefore, an
important starting point for understanding RB function is its structure, which acts as a
scaffold for these multiple protein interactions (FIG. 1).

Author Manuscript

Human RB contains 928 amino acids and is commonly described as having three domains.
The central domain was identified as the minimal region necessary to bind viral
oncoproteins, such as adenovirus E1A, SV40 TAg and human papilloma virus E7, and it
was named the ‘pocket’ (Ref. 9). The pocket comprises two subdomains, A and B, each
resembling a cyclin fold with three additional helices10 (FIG. 1a). The A and B subdomains
interact with each other through an extensive non‐covalent interface such that the pocket
folds into a single structural unit. Two additional cyclin folds constitute the structured
amino‐terminal domain (RBN), which resembles the pocket structure except for a few subtle
differences11. Approximately the last 150 residues of RB form the carboxy‐terminal domain
(RBC), which is intrinsically disordered12. There are several other sequences in RB that
similarly lack structure, including insertion loops in the RBN and the pocket, as well as a
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linker that flexibly tethers these two structured domains (FIG. 1b). The linker sequences are
notable because they contain CDK‐dependent phosphorylation sites (BOX 1) that have a
critical role for the inactivation of RB13,14. RB inactivation through phosphorylation and
reorganization of its structure is depicted in FIG. 1c (see below). The domain structure of the
RB family members p107 (also known as RBL1) and p130 (also known as RBL2) is similar,
which is consistent with their analogous functions in regulating growth, the cell cycle and
E2F function (BOX 2).
Evolutionarily conserved interaction surfaces on RB

Author Manuscript
Author Manuscript

The modular domain organization of RB, like that of many signalling proteins, allows for
independent binding and regulation of multiple protein interactors (FIG. 1). However, unlike
typical signal transducers, RB does not contain canonical protein–protein interaction
domains (for example, Src homology 2 and phosphotyrosine‐binding domains) and instead
uses the cyclin folds and the disordered RBC to form binding interfaces. To inhibit
transactivation, RB binds the E2F transactivation domain (E2FTD) using a highly conserved
region of the pocket domain, which lies at the interface between the A and B cyclin
folds15,16. Also in the pocket domain, an ‘L‐X‐C‐X‐E‐binding cleft’ (in which X represents
any amino acid) formed by three helices of the second cyclin fold binds an L‐X‐C‐X‐E
sequence found in viral proteins such as TAg and E7 (REFS 17,18). This interaction is
required for the cellular transforming activity of these proteins. The conservation of this
surface in RB orthologues from other species, as well as in its related family members p107
and p130, suggests a crucial cellular role (BOX 2). Importantly, a number of RB–protein
interactions have been mapped to the L‐X‐C‐X‐E‐binding cleft19,20. Although it has been
common to use the L‐X‐C‐X‐E sequence motif as a consensus for identifying cellular RB‐
interacting proteins, it has become clear from structural studies with viral and cellular
proteins that there are other determinants of high‐affinity interactions with the pocket cleft21.
Furthermore, several proteins that contact this region of RB do not contain a clear L‐X‐C‐X‐
E motif22,23, and there is little evidence that these or other L‐X‐C‐X‐E‐containing cellular
proteins bind RB directly. Together, these observations indicate that RB interactions with
cellular proteins at the L‐X‐C‐X‐E‐binding cleft are probably more complex than understood
from the crystal structures of RB bound to viral proteins. In light of the recent discovery of
small molecule therapeutics that can target the cleft24, further structural studies to
understand these subtleties are required.
Interactions through intrinsically disordered regions

Author Manuscript

RB binds several proteins using sequences in the RBN and RBC. The RBN binds E1A‐like
inhibitor of differentiation 1 (EID1), along with several other proteins, although data to map
protein interactions in detail are limited for this domain of RB. A second RB–E2F
interaction is made between the RBC and the ‘marked box’ domains of E2F and its
heterodimerization partner differentiation-related polypeptide (DP)12 (FIG. 1). Although the
RBC is intrinsically disordered, approximately 30 residues adopt a strand–turn–helix
conformation on binding the marked box region of E2F–DP. At least part of this second
interaction seems to be specific between RB and E2F1 in vivo, and it may be important for
the function and regulation of an E2F1‐specific activity, such as apoptosis25,26, which is
discussed below.
Nat Rev Mol Cell Biol. Author manuscript; available in PMC 2016 February 16.

Dick and Rubin

Page 4

Author Manuscript

The RBC is also the location of kinase and phosphatase docking sites27–29. These enzymes
bind short, linear peptide sequences distal to their target RB phosphorylation sites, and this
increases enzyme efficiency by a stronger substrate interaction. Distinct binding sites in the
RBC are accessed by cyclin A–CDK2, cyclin D–CDK4 and cyclin D–CDK6, although the
implications of this difference for CDK‐site preference by these enzymes is not clear27,29. A
recent structural study of protein phosphatase 1 (PP1) bound to the RBC demonstrated that
the phosphatase and cyclin A binding sites overlap and that PP1 can inhibit CDK activity
towards RB through a docking competition mechanism28. RB binds PP1 in a manner that
resembles other PP1 regulatory subunits, and it will be interesting to learn whether RB also
functions in targeting PP1 to specific substrates for dephosphorylation.

Cell cycle control through E2F regulation
Author Manuscript

Initial studies of RB focused on its inhibition of E2F transcription before the G1 to S phase
transition, as the observed negative regulation of the cell cycle offered a powerful
explanation for why RB is a tumour suppressor2,30. These early experiments correlated RB
function with its capacity to physically associate with E2F family proteins and thereby
inhibit E2F‐dependent activation of genes that stimulate DNA synthesis and cell cycle
advancement. When RB is in a hypophosphorylated state, pocket–E2FTD contacts and
interactions involving the RBC are required for E2F inhibition31,32. CDK‐dependent
phosphorylation, which occurs on approximately 13 conserved consensus sites in vivo33,
inactivates RB‐dependent E2F repression by dissociating the RB–E2F complex30 (BOX 1).
Regulation of RB–E2F binding

Author Manuscript
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Recent studies have characterized the structural changes in RB that result in binding
inhibition12–14 (FIG. 1c). Phosphorylation induces interdomain associations that occlude, or
allosterically disrupt, the E2FTD‐binding site in the pocket and the interaction between the
RBC and the E2F marked box. An important result of this is that discrete phosphorylation
events result in distinct RB structures. Ser608 and Ser612 phosphorylation stabilizes the
association of the pocket loop with the E2FTD‐binding site within the pocket domain.
Thr373 phosphorylation induces interdomain docking between the RBN and the pocket,
which allosterically inhibits E2FTD and directly inhibits binding at the L‐X‐C‐X‐E‐binding
cleft. Finally, Thr821 and Thr826 phosphorylation induces RBC binding to the pocket,
which excludes the E2F marked box and L‐X‐C‐X‐E interactions. It is possible that these
phosphorylation‐dependent conformational changes can control RB interactions with other
proteins as well as E2F. Mutational analysis of CDK phosphorylation sites on RB suggests
that a large number of sites need to be phosphorylated for RB inactivation and cell cycle
advancement34,35. However, there are few data available to indicate the quantity of sites that
are phosphorylated on each individual RB molecule during G1 to S phase transition. For this
reason, models such as the one depicted in FIG. 1c require further testing, and it is possible
that partial phosphorylation could create different functional outputs depending on which
specific sites are phosphorylated.
Unlike many other cell cycle regulatory proteins, RB is not typically degraded upon
inactivation but persists until mitosis, when it is dephosphorylated by PP1 to enter the
following G1 phase36. This presence throughout the cell cycle allows reactivation by
Nat Rev Mol Cell Biol. Author manuscript; available in PMC 2016 February 16.
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dephosphorylation in response to S phase and other checkpoints. Several recent studies have
found that other post‐translational modifications, including methylation and acetylation, can
control RB activity by regulating RB phosphorylation levels37 (BOX 1).
Chromatin structure regulation at E2F target promoters

Author Manuscript

RB interactions with chromatin‐regulating enzymes and histone‐modifying enzymes have
been identified and are mediated through the L‐X‐C‐X‐E‐binding cleft19. The physical
separation between the E2F and L‐X‐C‐X‐E‐binding surfaces in RB supports a model
whereby RB recruits chromatin regulators to E2F‐regulated promoters for repression or
activation of target genes (FIG. 2). CDK phosphorylation disrupts RB interactions with
these proteins by inducing conformational changes that inhibit binding at the L‐X‐C‐X‐E‐
binding cleft and E2Fs12,14,38,39. Mutations in the L‐X‐C‐X‐E‐binding cleft do not impair the
ability of RB to regulate the G1 to S phase transition and cell growth40, so the significance
of chromatin‐modifying enzymes in RB regulation of E2F‐controlled gene expression in
cycling cells is not clear. The action of these proteins may be more relevant for changes in
chromatin structure associated with permanent gene silencing observed in cell cycle exit.
Supporting this idea, a crucial role for RB–L‐X‐C‐X‐E interactions has been observed in the
formation of heterochromatin in senescence41, and RB and its homologues p107 and p130
contribute to the response of upstream signals that induce senescence and maintenance of
cell cycle exit42–44. Phenotypically, these results indicate an important role for RB in
recruiting chromatin regulators; however, biochemical demonstration of these complexes
remains rare. Recent work has now demonstrated the RB‐dependent recruitment of histone
deacetylase enzymes using its L‐X‐C‐X‐E‐binding cleft at E2F target genes by chromatin
immunoprecipitation assays45.

Author Manuscript

Transcriptional repression by other RB-family proteins in G1

Author Manuscript

RB belongs to a family comprising three homologous proteins that are referred to as pocket
proteins (BOX 2). p130 is the most abundant pocket protein in stable cell cycle arrest events
such as quiescence and senescence46,47. When bound to E2F4, it represses genes required
for cell cycle re‐entry under both conditions48,49. DREAM, a complex containing p130,
E2F4–DP and the highly conserved MuvB complex, was recently shown to facilitate this
p130‐dependent activity49,50. In human cells, chromatin immunoprecipitation assays showed
that MuvB proteins are located at most E2F‐regulated promoters, and gene expression
analysis has implicated DREAM as a repressor of cell cycle genes. Few details are known
about the biochemical function of MuvB, with the exception that it acts as a scaffold for the
recruitment of different transcription factors. DREAM is regulated by dual specificity Tyr‐
phosphorylation‐regulated kinase 1A (DYRK1A) and CDK phosphorylation51. Upon cell
cycle entry MuvB dissociates from p130 and binds Myb‐related protein B (MYBB; also
known as MYBL2) and forkhead box M1 (FOXM1)52,53. These two transcription factors,
which are upregulated in many cancers, then activate late‐stage cell cycle genes53.
Putting RB–E2F regulation into perspective
The canonical model of RB tumour suppression is based on the negative regulation of E2F
transcription54. However, p107 and p130 also repress E2F transcription and inhibit the cell
cycle, yet only RB is commonly mutated in cancer8. For this reason, some cancers may
Nat Rev Mol Cell Biol. Author manuscript; available in PMC 2016 February 16.
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retain the ability to restrict E2F activation. Two recent studies have also shown that activator
E2Fs (E2F1, E2F2 and E2F3) are dispensable for proliferation in vivo55,56. From this
perspective, it is difficult to envision how RB inhibition of these particular E2Fs can arrest
proliferation when they are not required for proliferation. These results suggest that
transcriptional regulation of E2Fs may not be the only way by wayRB can act as a tumour
suppressor. A number of novel RB activities have emerged, and they serve to illustrate the
multifunctional nature of this protein.

Cell cycle control through CDK inhibition

Author Manuscript
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An E2F‐independent mechanism for RB‐induced cell cycle arrest has recently been
uncovered. Ectopic expression of RB in an RB‐deficient cell line induces a G1 arrest before
E2F target genes become repressed57. Thus, progression through G1 can be blocked, and
CDKs can be inhibited, in an RB‐dependent fashion, without altering the transcription of
E2F gene targets. Two mechanisms, which are not mutually exclusive, have emerged to
explain this observation (FIG. 3). In the first case, the CDK inhibitor p27 (also known as
CDKN1B) is stabilized through the antagonism of its cognate F box protein, S phase kinaseassociated protein 2 (SKP2). In this model, RB physically binds SKP2 through its
unstructured RBC domain. This interaction prevents SKP2 from recognizing p27 and
targeting it for degradation via the ubiquitin–proteasome system (FIG. 3a,b). Consequently,
p27 is stabilized, causing CDK inhibition and cell cycle arrest57. In the second mechanism,
RB interacts simultaneously with SKP2 and the APC/C (anaphase‐promoting complex; also
known as the cyclosome)22. This interaction targets SKP2 for ubiquitylation and
degradation, leading to the stabilization of p27, CDK inhibition and cell cycle arrest. In this
model, again, RB acts as a scaffold, binding SKP2 at the RBC and the APC subunit CDC20
homologue 1 (CDH1) through the pocket (FIG. 3c). Although structural details of these
interactions have not been elucidated, RB mutagenesis studies suggest that CDH1 binding
involves the L‐X‐C‐X‐E‐binding cleft in the pocket22. The RB–CDH1 interaction was further
destabilized in an RB mutant that included mutations in both the L‐X‐C‐X‐E‐binding cleft
and the E2F‐binding site in the pocket. An interesting possibility is that the same RB
molecule cannot regulate E2F and APC–SKP2–p27 activities simultaneously. Studies
suggest that APC and E2F binding to RB may be competitive, although the complexity of
RB–E2F1 interactions described below suggests that this requires further investigation58.
Together, this mechanism of function and its apparent independence from E2F strongly
suggest that RB is a multifunctional protein. Future structural studies will be needed to fully
appreciate this mechanism and its regulation.
An E2F-independent paradigm of tumour suppression

Author Manuscript

To test the relevance of RB regulation of p27 in vivo, SKP2‐deficient mice were crossed
with animals heterozygous for Rb, and SKP2 loss was found to suppress cancer
susceptibility of the Rb+/− genotype59. Surprisingly, it was discovered that inactivation of
SKP2 in RB‐deficient cells did not inhibit proliferation, but rather induced a p27‐dependent
apoptotic programme. Apoptosis leads to loss of the intermediate lobe of the pituitary, which
is where tumours generally arise in Rb+/− mice. It is noteworthy that in these mice, cells
deficient in both RB and SKP2 exhibited deregulated E2F expression but not deregulated
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proliferation. Again, this result suggests that RB‐dependent regulation of non‐E2F pathways
is crucial. The existence of such pathways is more consistent with a multifunctional model
of RB and is less supportive of an E2F‐centric mechanism of function.

Heterochromatin and chromosome stability
RB has been shown to have an impact on genome stability through various distinct
mechanisms.
E2F-dependent mechanisms

Author Manuscript

Overexpression of the E2F target gene mitotic arrest deficient 2 (MAD2) as a consequence
of RB loss causes lagging chromosomes, in which chromosome arms become fused leading
to double‐strand DNA breaks or missegregation. These aberrations can result either from an
overactive spindle assembly checkpoint60 or from an inability to resolve merotelic
microtubule attachments to sister chromatids61. Furthermore, deregulation of E2F
transcription due to loss of RB function can lead to abnormally low nucleotide pools and
replication stress62. This stress leads to double‐strand DNA breaks and abnormal firing of
replication origins and, ultimately, causes aneuploidy. Thus, loss of RB function has several
negative effects on chromosome stability that are mediated by increased E2F activity, and
the mechanistic involvement of RB in genome maintenance in these scenarios is probably
best described by the classic mechanisms of E2F regulation described above. These
paradigms of RB function exemplify the idea that regulation of E2F is paramount to RB, and
that its diverse effects can ultimately be traced back to E2F control.
E2F-independent regulation of heterochromatin

Author Manuscript
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RB and its family members have emerged as regulators of heterochromatin domains that
surround the centromere and have a key role in chromosome structure and the attachment to
spindle microtubules. Cells deficient for all RB family proteins display decondensed
pericentromeric heterochromatin with reduced trimethylation of Lys20 on histone H4
(H4K20me3) as well as reduced DNA methylation63. This defect leads to tangled
chromosomes at metaphase, missegregation and aneuploidy. Many of these characteristics
are observed in cells from a mouse strain bearing an RB mutation that impairs its L‐X‐C‐X‐
E‐binding cleft but not its E2F interactions, indicating that this chromosomal phenotype is
caused by loss of just one aspect of RB function40 (FIG. 4). The root cause of this phenotype
remains uncertain. For example, loss of the histone tail modification H4K20me3 caused by
deletion of the methyl transferases SUV420H1 (suppressor of variegation 4–20 homologue
1) and SUV420H2 similarly depletes this modification from pericentromeric regions but
does not result in the chromosomal fusions seen in RB‐deficient cells64.
A series of recent reports have provided further insight into this aspect of RB function and
narrowed down the possibilities for how this mechanism works. First, examination of the
fruit fly orthologue of RB, called Rbf1, and comparison with fly mutations in components of
the condensin II complex revealed similar phenotypes of chromatin decondensation, not
only in mitotic chromosomes but also under growth arrest conditions23. This report
demonstrated a conserved interaction between RB and the condensin II complex in human
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and fly cells. Furthermore, loss of RB function leads to defective loading of condensin II and
cohesin, specifically at the centromeric region of mitotic chromosomes65–67. Phenotypically,
this is identifiable in mitosis as defective chromosome congression, reduced cohesion and
misaligned centromeres.

Author Manuscript

Beyond defects in cohesion and condensation of mitotic chromosomes, RB‐deficient cells
exhibit chromosome missegregation and aneuploidy. In addition to these mitosis‐specific
molecular defects, spontaneous double‐strand breaks are seen in cells deficient for all RB
family proteins67. These defects reveal the means by which RB loss can influence genome
stability independently of E2F transcriptional regulation. The effect of RB‐mediated genome
stability in cancer was investigated by crossing RB mutant mice that are viable but defective
for L‐X‐C‐X‐E inter actions with p53‐deficient mice66. In this way, compound mutant
animals, and p53 knockout‐only mice have similar G1 arrest defects. Compound mutant
animals obtained from this cross succumbed to cancer significantly earlier than their p53‐
knockout controls. Furthermore, tumours were more metastatic in mice deficient in both RB
and p53, and analysis of DNA copy number variation indicated that these mice had more
alterations. Thus, maintenance of genome stability through the regulation of pericentromeric
heterochromatin contributes to RB tumour suppressor activity.
Perspectives on RB regulation of chromosome stability

Author Manuscript
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First, it should be noted that loss of RB does not universally cause chromosome instability68.
Studies of primary retinoblastoma tumours propagated in mice indicate that, in this tumour
type, Rb‐null mutations do not contribute to chromosome instability. However, given the
relevance of the role of RB in cancer in a genomically unstable mouse model, understanding
the mechanism of RB function in establishing heterochromatin at pericentromeric regions is
vital. To this end, many fundamental questions remain (FIG. 3). Defects in condensin II and
cohesin loading are central to the effect of RB on chromatin structure, but there are no data
suggesting whether RB targets them to pericentromeric locations directly or regulates their
loading by another means. Furthermore, phosphorylation by CDKs in late G1 typically
inactivates RB by disrupting protein interactions2, so it is difficult to envision how RB
facilitates cohesion and condensation in M phase. Likewise, this aspect of RB function is
dependent on interactions at the L‐X‐C‐X‐E‐binding cleft, but the identity of the protein (or
proteins) that it associates with is unknown. The condensin II subunit chromosome‐
associated protein D3 (CAPD3) has been proposed as a candidate23, but there is little
evidence that it directly contacts RB. RB could also bind other proteins in the condensin II
ring or a separate bridging factor. Clearly, much work remains for us to understand this
newly emerging aspect of RB function. However, its independence from E2F transcriptional
regulation is well established and contributes to a growing body of literature that is revealing
the multifunctional nature of RB.

Regulation of apoptosis
Largely through the study of E2F overexpression in cultured mammalian cells and
deregulated E2Fs in RB‐knockout mice, it was discovered that E2Fs could induce
apoptosis69. More recently, it has been found that apoptotic phenotypes in Rb‐null mice are
secondary to defective placental development70, and hence are not exclusively caused by
Nat Rev Mol Cell Biol. Author manuscript; available in PMC 2016 February 16.
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overactive E2Fs. Almost simultaneously, new data have emerged describing a number of
post‐translational modification changes on E2F1 that allow it to respond to DNA damage
and induce cell death37. Specifically, E2F1 is phosphorylated by ataxia‐telangiectasia
mutated (ATM) and checkpoint kinase 2 (CHK2), two kinases that are activated by double‐
strand DNA breaks. E2F1 is also acetylated by p300/CBP‐associated factor (PCAF; also
known as KAT2B), an acetyltransferase that has been implicated in transcriptional control.
In addition, several basic residues on E2F1 are also demethylated in response to DNA
damage signalling. This level of regulation is unique to E2F1 as these modifications are not
shared by other E2F family members. In general, the ability of RB to bind and inhibit E2F1‐
dependent transcription has been interpreted as a means to block apoptosis, and this is
consistent with RB–E2F1 interactions ultimately mediating the effects of RB on cell
viability. However, recent mechanistic advances in our understanding of RB and E2F1 in
apoptosis now suggest multifunctional roles for these proteins.

Author Manuscript

DNA damage-induced alterations to RB–E2F1 function
A recent, transformative development in efforts to understand the role of RB in apoptotic
regulation has been the discovery that it can have a pro‐apoptotic role71. DNA damage
induces the recruitment of PCAF to RB and E2F1, resulting in histone acetylation and
transcription at specific pro‐apoptotic promoters. To understand how RB can regulate both
apoptosis and the cell cycle in response to different stimuli, it is important to consider how it
regulates E2F1 in normal proliferating cells and how E2F1 control is altered in response to
DNA damage.

Author Manuscript

The biochemical mechanism of E2F1 interactions with RB is different from that of other
E2Fs. E2F1 was the E2F protein that was used to define the association between the RB
pocket and the transactivation domain of E2F72. However, E2F1 has an additional
interaction with RB that is unique among E2F family members25 (FIG. 5a). The best
evidence for the unique RB–E2F1 interaction is the demonstration that the adenoviral E1A
protein can compete with and disrupt the common RB–E2F interaction but not the E2F1‐
specific interaction73. Likewise, RB–E2F1 association persists when RB is
phosphorylated74. The structural determinants for the specific RB–E2F1 interaction have
been mapped to the RBC26. However, it is unclear to what extent the crystal structure of the
RBC complex with the E2F1–DP1 marked box domains represents the E2F1‐specific
interaction12,74.

Author Manuscript

The picture that has emerged from this differential regulation of E2F1 by RB is that CDK
phosphorylation of RB releases most E2Fs from its control at the G1 to S phase boundary to
stimulate transcription of cell cycle target genes, but at least some E2F1 remains bound to
RB through the unique interaction of these proteins in S phase (FIG. 5b). This model
explains a number of paradoxical reports that previously suggested RB–E2F1 interactions
persist in S phase, even in the face of CDK phosphorylation75–77. The unique RB–E2F1
interaction seems to negatively regulate transcription at pro‐apoptotic promoters, such as
TAp73, in reporter assays74. In response to DNA damage, both RB and E2F1 undergo
extensive changes in post‐translational modifications37. RB is dephosphorylated at CDK
target sites but is phosphorylated by CHK2, as well as acetylated and methylated. E2F1 is
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phosphorylated and acetylated as described above. The cumulative effect results in
repression of the transcription of E2F‐dependent cell cycle genes and the activation of pro‐
apoptotic genes (FIG. 5c). How these modifications lead to persistence of only the specific
RB–E2F1 complex is unknown; however, two reports now demonstrate that a complex
containing phosphorylated RB and E2F1 has pro‐apoptotic activity and is found at the
TAp73 promoter coincident with its activation71,78.
Further experimentation to understand the molecular mechanism of RB–E2F1
transcriptional regulation will continue to be a challenging endeavour. It represents an area
in which RB is again emerging as more than just an E2F regulator that is controlled by CDK
phosphorylation. A deeper molecular understanding of RB–E2F1 interactions and regulation
will undoubtedly clarify its role in apoptosis and the DNA‐damage response and offer
further evidence for the multifunctional nature of RB.

Author Manuscript

Reassessing the uses of RB function in cancer

Author Manuscript

Tumour specimens are often graded on proliferative indexes, and high levels of proliferating
cells are generally correlated with poor outcomes. Recent advances in genomic analyses of
tumours have established expression signatures that are indicative of deregulation of E2F
activity79,80. However, no markers are available that predict the ability of cancer cells to
activate RB and restrict proliferation, or that predict its potential to stimulate apoptosis and
eliminate tumours. Given the direct effect of genotoxic chemotherapeutics and novel kinase‐
inhibitor drugs for growth and survival pathways that affect RB and its downstream
effectors, more rigorous classification of the functional state of RB in tumours will be
beneficial for clinical outcomes. Furthermore, the key role of RB–E2F1 in regulating TAp73
expression in response to DNA damage offers tremendous potential for the development of
therapeutics, as TAp73 expression has been shown to control sensitivity to genotoxic
therapeutics81. A clearer structural picture of RB and E2F1 in their various interaction
configurations will create the opportunity for therapeutic manipulation.

Conclusions and perspectives

Author Manuscript

Recent structural and functional data highlighted here are beginning to provide evidence that
RB is a truly multifunctional protein. Current data also suggest that some novel functions of
RB are potentially tumour suppressive. The RB–SKP2–p27 regulatory pathway is,
seemingly, an E2F‐ independent proliferative control mechanism. Initial experiments
demonstrate that CDH1 and E2F compete for RB association58, and this type of biochemical
insight defines RB as multifunctional. It is not clear whether CDK regulation through the
RB–SKP2–p27 pathway is equivalent in importance with E2F transcriptional repression.
The best available data suggest that both pathways affect the pituitary, but it is not yet
possible to determine whether one pathway has a relatively more important role in a
particular tissue. It is also possible that the RB–E2F and RB–SKP2–p27 pathways are
crucial under distinct physiological circumstances that have yet to be determined.
A similar comparative discussion is possible for each of the different RB‐dependent
pathways described in this Review, and others that do not yet have an extensive structural
understanding. Can RB engage in each one simultaneously as a higher order complex, or are
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their interactions mutually exclusive, forcing cellular RB to be rationed among its different
roles? Given the growing support for multifunctionality of RB, the next challenges in cell
cycle and RB research will be to assign priority to these functions. Does RB rely more
strongly on one function compared with others to act as a tumour suppressor? Only through
the understanding and comparison of all functions in relation to one another will we
appreciate the tumour suppressive role of RB in biochemical detail.
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Glossary
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Cyclin

A family of proteins that activate cyclin-dependent kinases and
whose stability is cell-cycle regulated.

CDK

(Cyclin-dependent kinase). A family of kinases that are activated
by cyclins.

E2F

(E2-binding factor). A family of cell-cycle regulated
transcription factors.

Pocket

A region in RB-family proteins that was originally determined to
bind to viral oncoproteins such as SV40 TAg

Differentiationrelated polypeptide

(DP). The E2F dimerization partner.

Pocket proteins

RB-family proteins defined by their possession of the central
‘pocket’ domain

p27

An inhibitor of cyclin-dependent kinase activity.

F box protein

A protein containing the F box domain an approximately 50amino acid motif that facilitates protein–protein interactions

S phase kinaseassociated protein 2

(SKP2). An adaptor protein that recruits p27 to the SKP–cullin–
F box E3 ligase complex.

APC/C

(Anaphase-promoting complex also known as the cyclosome).
An E3 ubiquitin ligase.

Merotelic

When multiple microtubules emanating from opposite spindle
poles, simultaneously bind to a single kinetochore

Aneuploidy

An abnormal number of chromosomes in a cell.

Centromere

A constricted region of a chromosome that interacts with
kinetochores and is the attachment point for spindle
microtubules.
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Condensin II

A protein complex made up of seven protein subunits that create
a ring structure to link and supercoil DNA strands.

Cohesin

A ring-structured protein complex similar to the condensins that
creates cohesion between replicated homologous DNA strands
and regulates their separation during cell division

Pericentromere

A repetitive chromosomal region adjacent to the centromere.
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Box 1
RB post-translational modifications

Author Manuscript

Post-translational modifications have an important role in the regulation of RB function.
With a few exceptions, RB phosphorylation (P) results in inactivation, transcriptional
derepression and cell cycle progression30. RB is phosphorylated by several different
kinases, including cyclin-dependent kinases (CDKs) and checkpoint kinase 2 (CHK2)37.
Phosphorylation controls RB interactions with other proteins. This modification typically
occurs outside structured domains (see the figure) and promotes conformational
transitions from disordered to ordered RB structures that mask protein-binding
surfaces12–14 (FIG. 1). Different kinases show preferences for particular phosphorylation
sites, and discrete phosphorylation events induce specific structural changes. However, it
remains uncertain whether, and in what context, differentially phosphorylated isoforms of
RB exist in the cell.

Author Manuscript

Acetylation (Ac) and methylation (Me) sites have been identified in disordered sequences
towards the RB carboxy-terminal domain (RBC)37. In contrast to phosphorylation, these
modifications occur in response to signals, such as DNA damage and differentiation,
which correlate with RB activation and repression of gene expression82–86. Acetylation
occurs on Lys873 and Lys874, which are located within the cyclin-docking sequence,
and results in reduced phosphorylation, probably through kinase inhibition83,84.
Methylation on Lys873 and Lys810 by SET-domain methyltransferases similarly results
in RB hypophosphorylation82,85. SET and MYND domain-containing 2 (SMYD2)
methylates Lys860, which results in the recruitment of the transcriptional repressor
lethal(3)malignant brain tumour-like 1 (L3MBTL1)86. The reader is referred to other
reviews for more details on these and other emerging post-translational modifications on
RB and their roles in the regulation of function33,37.
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RBN, RB amino-terminal domain.
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Box 2
The RB family of proteins

Author Manuscript

RB, p107 and p130 are collectively known as the ‘pocket protein’ family. RB shares
approximately 25% sequence identity with both homologues, whereas p107 and p130
share approximately 54% identity with each other. Structural data characterizing p107
and p130 are limited; however, sequence analysis suggests domains comparable to those
in RB are present (see the figure). Both proteins contain predicted amino-terminal
domains (107N and 130N), pocket domains and carboxy-terminal domains (107C and
130C), with analogous secondary and tertiary structural elements. Consistent with these
parallel structural features, a number of common molecular functions have been
identified87,88. All three proteins negatively regulate the cell cycle, and for each protein
this effect has been tied to its ability to associate with E2F transcription factor family
members and influence E2F-mediated gene expression. The pocket domains of all
homologues are predicted to contain L-X-C-X-E-binding clefts, which bind viral proteins
and probably partially overlapping sets of cellular proteins. Pocket proteins are all
inactivated by cyclin-dependent kinases (CDKs), and sequence analysis suggests several
common structural effects of phosphorylation.

Author Manuscript

Genetic and cellular investigations have revealed various key functional differences
between pocket proteins. RB knockout is embryonic lethal in mice, whereas knockout of
p107 or p130 does not have a phenotype in a mixed genetic background89–91.
Examination of mice lacking different combinations of pocket protein genes suggests that
p107 and p130 have an overlapping role in development that is distinct from that of
RB91. Importantly, the tumour suppressor properties of the RB gene are significantly
stronger than those of p107 and p130, and only RB mutations are commonly found in
human cancer. Consistent with these genetic differences, pocket proteins have been
observed to control distinct E2F target genes and arrest cells in different cell cycle
phases47. In a recent striking example, a genome-wide screen of gene repression in
fibroblast cells revealed a unique role for RB in promoting senescence42. Further
structural and biochemical analysis is needed to understand the molecular basis for these
functional differences in pocket proteins, although distinct protein interactions have
already been identified. For example, pocket proteins show preferences for different E2F
family members, and p107 and p130 bind and inhibit CDKs, whereas RB exclusively
forms a stable complex with protein phosphatase 1 (PP1)28,87,88.
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RBC, RB carboxy-terminal domain; RBN, RB amino-terminal domain.
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Figure 1. RB is a multidomain protein with several distinct protein-binding surfaces

a | Model of active and complexes with E2F and an ‘L-X-C-X-E’ peptide (Protein Data
Bank (PDB) codes: 2QDJ, 1GUX, 1N4M and 2AZE). The dashed lines indicate flexible
interdomain linkers. b | Schematic diagram of the domain structure and location of known
binding sites for protein partners. c | Schematic structure of RB in its inactivated,
phosphorylated conformation. Thr373 phosphorylation drives interdomain docking of the
RB amino-terminal domain (RBN) and the ‘pocket’, whereas Ser608 and Ser612 and
Thr821 and Thr826 phosphorylation induce binding of the pocket loop and the RB carboxyterminal domain (RBC), respectively, to the pocket domain. These different conformational
changes inhibit specific RB–protein interactions. CDH1, CDC20 homologue 1; CDK,
cyclin-dependent kinase; DPMB, differentiation-related polypeptide marked box; E2FTD,
E2F transactivation domain; EID1, E1A-like inhibitor of differentiation 1; PP1, protein
phosphatase 1.
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Figure 2. Regulation of E2Fs by RB
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In the G1 phase of the cell cycle, RB is phosphorylated at low levels and associates with
E2F transcription factors, which are dimeric proteins containing E2F and differentiationrelated polypeptide (DP) subunits. RB also recruits enzymes that regulate chromatin
structure to these complexes. Transcription of these genes is repressed until cyclindependent kinases (CDKs) phosphorylate (P) RB and prevent binding of E2Fs and
chromatin regulators. E2F transcription factors then transcribe genes necessary for S phase
and the cell cycle advances. RBC, RB carboxy-terminal domain; RBN, RB amino-terminal
domain.
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Figure 3. Transcription-independent regulation of cyclin-dependent kinases by RB
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a | Schematic depiction of the F box protein S phase kinase-associated protein 2 (SKP2)
recognizing phosphorylated p27. Binding results in ubiquitylation and degradation of p27
and the activation of cyclin-dependent kinases (CDKs). b | SKP2 is bound by the RB
carboxy-terminal domain (RBC) and the ‘pocket’ domain, which competes with SKP2 for
interaction with phosphorylated p27. RB thereby prevents p27 ubiquitylation, resulting in
inhibition of CDK activity. c | The RBC region also binds SKP2 to recruit it to the APC/C
(anaphase-promoting complex; also known as the cyclosome) E3 ubiquitin ligase complex.
Ubiquitylated SKP2 (not shown) is targeted for degradation, leading to the increased
expression of p27 and inhibition of CDKs. RBN, RB amino-terminal domain.
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Figure 4. Regulation of pericentromeric heterochromatin by RB
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The condensin II complex is enriched at pericentromeric and centromeric regions of mitotic
chromosomes. Loading this complex onto chromatin is dependent on L-X-C-X-E-type
interactions with RB. How this directs the condensin II complex to this genomic location is
not known (indicated by a question mark), but it is suggested that additional proteins are
involved. Similarly, the localization of cohesins to the centromere and pericentromere
remains to be elucidated. Given the prominence of genome instability in mice deficient for
L-X-C-X-E-type interactions, RB function in chromosome structure is key for the wellconserved L-X-C-X-E binding site. RBC, RB carboxy-terminal domain; RBN, RB aminoterminal domain.
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Figure 5. Differential regulation of E2F1 in apoptosis
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a | RB associates with E2F transcription factors and differentiation-related polypeptide (DP)
heterodimers in G1 to repress transcription of cell cycle genes. RB can also form a unique
interaction with E2F1 involving sequences in the RB carboxy-terminal domain (RBC). b | In
S phase, RB is phosphorylated (P) and unable to bind to E2Fs that are bound the promoters
of cell cycle genes, allowing the cell cycle to advance. Phosphorylated RB can still interact
with E2F1, and this complex can repress the expression of apoptotic target genes. c | In
response to DNA damage, RB is dephosphorylated and regains the ability to repress E2F
transcription at cell cycle promoters. Simultaneously, phosphorylated RB remains in contact
with E2F1 transcription factors, and the recruitment of p300/CBP-associated factor (PCAF)
through unknown signals leads to histone acetylation (not shown) and activation of proapoptotic target genes. RBN, RB amino-terminal domain.
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